Patents
Hematopoietic stimulation
Patent Number: 6300314CD26 is an ectoenzyme that is found on numerous cells including stem cells. The enzyme performs numerous functions that inhibit stem cell proliferation. This patent provides a composition of matter that potently inhibits the CD26 ectoenzyme activity and thereby stimulates proliferation of hematopoietic stem cells. This patent would be very useful for stimulation of other types of stem cells...
Inventors: Wallner, Barbara P. (Weston, MA); Jones, Barry (Cambridge, MA); Miller, Glenn T. (Haverhill, MA); Adams, Sharlene (Watertown, MA)
Assignee: Point Therapeutics, Inc. (Boston, MA)
Date of First Priority Issue: Monday May 4th, 1998
Use of multipotent neural stem cells and their progeny for the screening of drugs and other biological agents
Patent Number: 6294346Great advances in combinatorial chemistry and in silico design have fast outpaced the availability of biological systems that can be screened using high-throughput systems. In this patent various neural stem cells and their progeny are claimed for use as screening targets in drug discovery.
Inventors: Weiss, Samuel (Calgary, CA); Reynolds, Brent (Calgary, CA); Hammang, Joseph P. (Barrington, RI); Baetge, E. Edward (Barrington, RI)
Assignee: Neurospheres Holdings, Ltd. (Alberta, CA)
Date of First Priority Issue: Monday July 8th, 1991
Treatment for juvenile diabetes
Patent Number: 6288301This patent teaches how to treat diabetes by the activation of endogenous stem cells through administration of gastrin and EGF. This patent is in clinical trials.
Inventors: Nardi, Ronald V. (Sudbury, MA); Brand, Stephen J. (Lincoln, MA) )
Assignee: Waratah Pharmaceuticals, Inc. (CA); The General Hospital Corporation (Boston, MA
Date of First Priority Issue: Monday December 14th, 1992
Method of preparing suppressor T cells with allogeneic mesenchymal stem cells
Patent Number: 6281012This patent covers the use of mesenchymal stem cells to generate T suppressor cells in general. Specifically it mentions that CD8 positive T cells can be turned into suppressor cells by contact with mesenchymal stem cells. Usually, T suppressor cells are called T regulatory cells and this refers to CD4+ CD25+ cells. CD8+ T suppressor cells were very popular in the 1970s and 1980s but then...
Inventors: McIntosh, Kevin (Ellicott City, MD); Klyushnenkova, Elena (Baltimore, MD)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Tuesday October 12th, 1999
Hematopoietic differentiation of human pluripotent embryonic stem cells
Patent Number: 6280718This patent covers ways of inducing the generation of hematopoietic stem cells from embryonic stem cells. This is very useful since it may be possible to generate allogeneic hematopoietic stem cells for the whole population using such a method.
Inventors: Kaufman, Dan S. (Madison, WI); Thomson, James A. (Madison, WI)
Assignee: WARF
Date of First Priority Issue: Sunday November 8th, 1998
Factor IX delivery method using bone marrow-derived cells
Patent Number: 6277369This patent teaches how to transfect hematopoietic stem cells with various genes, including the gene for Factor IX. Transfection is performed by first treating the stem cells with TGF beta in order to increase rate of DNA incorporation.
Inventors: Gordon, Erlinda M. (Glendale, CA); Anderson, W. French (San Marino, CA); Hall, Frederick L. (Glendale, CA)
Assignee: University of Southern California (Los Angeles, CA)
Date of First Priority Issue: Tuesday November 12th, 1996
Ischemia detection system
Patent Number: 6277082This patent provides a medical device that detects ischemia based on electrical conductivity and other parameters. This invention is useful in combination with stem cell therapy so as to enable the administrator of stem cell angiogenic therapy to decide when and where therapy is needed.
Inventor: Gambale, Richard A. (Tyngsboro, MA)
Assignee: C. R. Bard, Inc. (Murray Hill, NJ)
Date of First Priority Issue: Thursday July 22nd, 1999
Compositions, kits, and methods for modulating survival and differentiation of multi-potential hematopoietic progenitor cells
Patent Number: 6261841This patent teaches that administration of prolactin may be used for enhancing hematopoiesis. This is interesting since there are other patents, including by Stem Cell Therapeutics, that teach the use of prolactin and other compounds for stimulation of neural stem cells.
Inventors: Cohen, Isaac (Wilmette, IL); Lefebvre, Phil (Chicago, IL); Lin, Jiandie (Evanston, IL); Linzer, Daniel (Evanston, IL)
Assignee: The Board of Trustees of Northwestern University (Evanston, IL)
Date of First Priority Issue: Friday June 25th, 1999
Human mesenchymal stem cells from peripheral blood
Patent Number: 6261549In the same way that hematopoietic stem cells can be purified from peripheral blood, and in the same way that they can be mobilized, this patent teaches that the concept is also applicable to mesenchymal stem cells.
Inventors: Fernandez, Mireya (Santiago, CL); Minguell, Jose J. (Santiago, CL)
Assignee: Osiris Therapeutics, Inc. (Baltimore, MD)
Date of First Priority Issue: Thursday July 3rd, 1997
Stimulation of hematopoietic cells in vitro
Patent Number: 6258597The enzyme dipeptidyl peptidase is expressed on a variety of cells including stem cells. This enyzme inhibits the ability of stem cells to proliferate. This patent provides an "inhibitor of inhibitor" so as to stimulate stem cell proliferation.
Inventors: Bachovchin, William (Melrose, MA); Wallner, Barbara (Weston, MA)
Assignee: Point Therapeutics, Inc. (Boston, MA)
Date of First Priority Issue: Monday September 29th, 1997